Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001104659-24-130182
Filing Date
2024-12-19
Accepted
2024-12-19 16:27:49
Documents
5
Effectiveness Date
2024-12-19

Document Format Files

Seq Description Document Type Size
1 FORM S-8 tm2431354d1_s8.htm S-8 50738
2 EXHIBIT 5.1 tm2431354d1_ex5-1.htm EX-5.1 9586
3 EXHIBIT 23.1 tm2431354d1_ex23-1.htm EX-23.1 1793
4 EX-FILING FEES tm2431354d1_ex-filingfees.htm EX-FILING FEES 12378
5 GRAPHIC tm2431354d1_ex5-1img001.jpg GRAPHIC 3128
  Complete submission text file 0001104659-24-130182.txt   80313
Mailing Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Filer) CIK: 0001566044 (see all company filings)

EIN.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-283940 | Film No.: 241563697
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)